HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koller, W. C. Articles by Vetere-Overfield, B. Search for Related Content PubMed PubMed Citation Articles by Koller, W. C. Articles by Vetere-Overfield, B.

Acute and chronic effects of propranolol and primidone in essential tremor

From the Department of Neurology, University of Kansas Medical Center, Kansas City, KS.

We studied the acute and chronic effects of propranolol and primidone in essential tremor by administering long-acting propranolol (80 to 160 mg/d) and primidone (50 to 250 mg/d) to 50 patients. We evaluated patients at 1, 3, 6, 9, and 12 months after treatment and assessed tremor by subjective rating by patients, clinical scoring, and tremorgraphic (accelerometer) recordings. Acute adverse reactions occurred in 8% with propranolol and 32% with primidone. Propranolol was without therapeutic effect in 30%, and 32% had no benefit from primidone. Significant chronic side effects occurred in 17% taking propranolol and in 0% with primidone. Tolerance to drug effect occurred with chronic treatment in 12.5% of patients with propranolol and 13.0% with primidone. We conclude that propranolol and primidone are effective long-term treatment for some patients with essential tremor. Acute adverse reactions with primidone and side effects with chronic use of propranolol hamper therapy.

Address correspondence and reprint requests to Dr. Koller, Department of Neurology, University of Kansas Medical Center, 39th and Rainbow Boulevard, Kansas City, KS 66103.

Received April 17, 1989. Accepted for publication in final form May 26, 1989.

This article has been cited by other articles:

				A. Gironell and J. Kulisevsky Review: Diagnosis and management of essential tremor and dystonic tremor Therapeutic Advances in Neurological Disorders, July 1, 2009; 2(4): 215 - 222. [Abstract] [PDF]

				J. J. Chen and D. M. Swope Essential Tremor Journal of Pharmacy Practice, December 1, 2007; 20(6): 458 - 468. [Abstract] [PDF]

				W. G. Ondo, J. Jankovic, G. S. Connor, R. Pahwa, R. Elble, M. A. Stacy, W. C. Koller, L. Schwarzman, S. -C. Wu, J. F. Hulihan, et al. Topiramate in essential tremor: A double-blind, placebo-controlled trial Neurology, March 14, 2006; 66(5): 672 - 677. [Abstract] [Full Text] [PDF]

				G. K. Bergey Initial treatment of epilepsy: Special issues in treating the elderly Neurology, November 23, 2004; 63(10_suppl_4): S40 - S48. [Abstract] [Full Text]

				E. D. Louis Essential Tremor N. Engl. J. Med., September 20, 2001; 345(12): 887 - 891. [Full Text] [PDF]

				G. Deuschl New Treatment Options for Tremors N. Engl. J. Med., February 17, 2000; 342(7): 505 - 507. [Full Text]

				E. D. Louis A New Twist for Stopping the Shakes?: Revisiting GABAergic Therapy for Essential Tremor Arch Neurol, July 1, 1999; 56(7): 807 - 808. [Full Text] [PDF]

				M. Hallett Classification and Treatment of Tremor JAMA, August 28, 1991; 266(8): 1115 - 1117. [Abstract] [PDF]